JPRN-UMIN000002763已完成2 期
Phase II study of Amrubicin in patients with Small-Cell Lung Cancer that is refractory or relapsed within 90 days of completing previous treatment (JCOG0901) - Phase II study of Amrubicin in patients with Small-Cell Lung Cancer that is refractory or relapsed within 90 days of completing previous treatment (JCOG0901)
Japan Clinical Oncology Group(JCOG)0 个研究点目标入组 80 人开始时间: 2009年11月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) active concomitant malignancy 2) active infection 3) fever 4) pregnancy or lactation 5) serious psychiatric illness 6) steroid treatment 7) massive pleural or pericardial effusion 8) symptomatic brain metastasis 9) interstitial pneumonia or severe pulmonary emphysema 10) ileus 11) myocardial infarction within 6 months or unstable angina 12) uncontrollable hypertension 13) uncontrollable diabetes mellitus
研究者
相似试验
已完成
2 期
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)JPRN-UMIN000005342Japan Clinical Oncology Group (JCOG)80
已完成
2 期
Phase II study of gemcitabine alone in locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG 0506)pancreatic neoplasmJPRN-C000000308Japan Clinical Oncology Group(JCOG)50
已完成
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in advanced biliary tract cancer. (JCOG 0805)biliary tract neoplasmJPRN-UMIN000001685Japan Clinical Oncology Group(JCOG)100
已完成
2 期
Phase II study of ABVd therapy for the previously untreated patients with stage II to IV Hodgkin' s disease (JCOG 9305, LSG14)JPRN-C000000092Japan Clinical Oncology Group(JCOG)108
已完成
2 期
Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma(JCOG1105, IMPROVE-MPB study)Elderly patients or non-elderly patients refusing transplant with untreated symptomatic myelomaJPRN-UMIN000011180Japan Clinical Oncology Group (JCOG)91